CN101590182A - The application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level - Google Patents
The application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level Download PDFInfo
- Publication number
- CN101590182A CN101590182A CNA2008100551865A CN200810055186A CN101590182A CN 101590182 A CN101590182 A CN 101590182A CN A2008100551865 A CNA2008100551865 A CN A2008100551865A CN 200810055186 A CN200810055186 A CN 200810055186A CN 101590182 A CN101590182 A CN 101590182A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- pericarpium citri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level.Chinese medicine composition of the present invention is made up of 11 flavor Chinese medicines such as the Radix Astragali, Radix Ginseng, Radix Salviae Miltiorrhizae, can effectively reduce the level of heart failure patient endothelin level (ET) and tumor necrosis factor (TNF-α).
Description
Technical field
The present invention relates to a kind of new purposes of Chinese medicine composition, particularly, relate to the application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level.
Background technology
The fundamental mechanism that causes heart failure that development takes place is that ventricle is reinvented.It is because the molecule of a series of complexity and the variation that cell mechanism causes myocardial structural, function and phenotype that ventricle is reinvented.These variations comprise: neuroendocrine activation (as Angiotensin II, Endothelin, tumor necrosis factor, oxygen-derived free radicals and malonaldehyde etc.), hemodynamic change, apoptosis of cardiac muscle and the Ultrastructural variation of myocardial cell etc.
Modern medicine is thought, Endothelin (ET) is present the most intensive known vasoconstrictive factor, not only directly stimulate or activate multiple hormone and cytokine, and the pathophysiological process of participation cardiovascular disease, clinical and experimentation shows that it plays an important role in bringing out the process that increases the weight of heart failure.Tumor necrosis factor (TNF-α) is the cytokine of polytype cell performance multiple-effect, and hemodynamics and neuroendocrine can promote macrophage to produce TNF-α unusually during heart failure, and TNF-α is raise.
Chronic heart failure (chronic heart failure, CHF) time, vascular endothelium dysfunction, the blood vessel wall shearing stress changes, ischemia, the activation of anoxia and the various kinds of cell factor and endocrine factor all can stimulate the synthetic and release of ET by the adjusting to ET genetic transcription and expression, pulmonary circulation silt coffee and renal perfusion descend during CHF, the metabolism of knowing of ET is descended, the ET that raises can make the myocardial cell hypertrophy, induce myocardial cell embryo type expression of gene, influence fibroblastic collagen anabolism, cause myocardium interstitial fibrosis, constitute the pathologic basis of remodeling ventricle.ET also has direct toxicity and arrhythmogenic effect to myocardial cell.TNF-a is by the excretory a kind of cell agonist of activatory mononuclear phagocyte, can damage blood vessel endothelium, suppresses myocardial contraction, causes right ventricle obviously to enlarge, and stimulates the fibroblast increment, participates in the pathological process of remodeling ventricle, promotes the ET secretion simultaneously.During heart failure, the impaired negative effect important of the function of the neuro humor factor, cytokine and local endotheliocyte to lapsing to of disease.(Zhao Shunfeng. blood plasma brain sodium skin, atrial natriuretic peptide, endothelin-1 and the research of tumor necrosis factor joint-detection in patients with congestive heart failure. medical test and the 18th the 4th phase of volume of clinical .2007 .)
Endothelin that is produced in the heart failure process and tumor necrosis factor etc. are all harmful to body, therefore, we are referred to as malignant cytokine with generation in the heart failure process to the deleterious cytokine of body, and Endothelin and tumor necrosis factor all belong to wherein a kind of.
The present invention is the improvement invention of carrying out on the basis of Chinese patent ZL 02146573.8, quotes in full the content of this patent document record at this.Chinese patent ZL 02146573.8 does not put down in writing the application of this Chinese medicine composition in the medicine of preparation reduction malignant cytokine level.The invention provides the new application of this Chinese medicine composition in the medicine of preparation reduction malignant cytokine level.
Summary of the invention
The object of the invention provides the application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level;
Preferably, this Chinese medicine composition can effectively reduce heart failure patient endothelin level (ET) and tumor necrosis factor (TNF-α) level.
Medicine of the present invention is to select for use 11 herbal medicines such as the Radix Astragali, Radix Ginseng, Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae to form, and has warming yang for resolving fluid retention, the effect of benefiting QI for activating blood circulation.
Described Chinese medicine composition is made by following bulk drugs:
Radix Astragali 150-450 part, Radix Aconiti Lateralis Preparata 40-120 part, Radix Ginseng or Radix Codonopsis 75-225 part, Radix Salviae Miltiorrhizae 75-225 part, Semen Lepidii (Semen Descurainiae) 50-150 part, Cortex Periplocae or CORTEX ACANTHOPANACIS 60-180 part, Rhizoma Alismatis 75-225 part, Rhizoma Polygonati Odorati 25-75 part, Ramulus Cinnamomi 30-90 part, Flos Carthami 30-90 part, Pericarpium Citri Reticulatae 25-75 part;
Preferably, described Chinese medicine composition is made by following bulk drugs:
450 parts of the Radixs Astragali, 112.5 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 225 parts of Radix Codonopsis, 225 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 180 parts of CORTEX ACANTHOPANACIS, 225 parts of Rhizoma Alismatis, 75 parts of Rhizoma Polygonati Odorati, 90 parts of Ramulus Cinnamomi, 90 parts on Flos Carthami, 75 parts of Pericarpium Citri Reticulataes;
Preferably, described Chinese medicine composition is made by following bulk drugs:
250 parts of the Radixs Astragali, 112.5 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 200 parts of Radix Codonopsis, 120 parts of Radix Salviae Miltiorrhizaes, 135 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 150 parts of CORTEX ACANTHOPANACIS, 200 parts of Rhizoma Alismatis, 60 parts of Rhizoma Polygonati Odorati, 75 parts of Ramulus Cinnamomi, 75 parts on Flos Carthami, 60 parts of Pericarpium Citri Reticulataes.
The active component of Chinese medicine composition of the present invention can be made by the extraction process of routine [as model Bi Ting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition)], more preferably, the active component of described Chinese medicine composition is made up of the effective ingredient that the following step makes:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng or Radix Codonopsis, Cortex Periplocae or CORTEX ACANTHOPANACIS are doubly measured 70% ethanol extraction with 7-9, filter, concentrated extracting solution to relative density when 60 ℃ of heat are surveyed is the clear paste of 1.25-1.30;
(2) volatile oil of extraction Ramulus Cinnamomi, Pericarpium Citri Reticulatae;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 6-10 times of water gaging decoction 2 times, and each 2 hours, merge extractive liquid, filtered; The aqueous solution that Ramulus Cinnamomi, Pericarpium Citri Reticulatae are carried behind the oil filters, and collects aqueous solution filtrate, adds 6-10 times of water gaging again and decocts residue 1 hour, filters, and merges aqueous solution; The various aqueous solutions of above-mentioned gained are merged, and being concentrated into relative density is the 1.25-1.30 clear paste, adds ethanol in the stirring, to determining alcohol 70%, leaves standstill, and filters, and filtrate is concentrated into that relative density is the 1.25-1.30 clear paste when 60 ℃ of heat are surveyed.
The present invention also provides the preparation method of this Chinese medicinal composition capsules agent:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng or Radix Codonopsis, Cortex Periplocae or CORTEX ACANTHOPANACIS are proportionally measured take by weighing and added 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid,, filter, decompression filtrate recycling ethanol is concentrated into relative density and is the clear paste of 1.25-1.30 (60 ℃ of heat are surveyed), and is standby;
(2) Ramulus Cinnamomi, Pericarpium Citri Reticulatae distillating extracting oil proportionally, the aqueous solution of carrying behind the oil filters, and standby, residue adds 8 times of water gagings again and decocted 1 hour, filters, and merges decocting liquid, and is standby;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 9 times of amount decoctions of water 2 times, each 2 hours, merge extractive liquid,, filter, merge with Ramulus Cinnamomi, Pericarpium Citri Reticulatae decocting liquid in the step (2), being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, add ethanol in the stirring, left standstill below 70%, 4 ℃ 24 hours to determining alcohol, filter, decompression filtrate recycling ethanol, being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, mixes 65-70 ℃ of oven dry with the alcohol extraction clear paste of step (1);
(4) step (3) gained dried cream powder is broken into 100 order powder, adds 70% ethanol and granulate in right amount, spray into Ramulus Cinnamomi, Pericarpium Citri Reticulatae volatile oil, mixing, encapsulated, promptly.
In the Chinese medicine composition of the present invention, as the latin name of the crude drug of active component and processing method thereof from " Chinese medicine voluminous dictionary " (in July, 1977, front page, Shanghai science tech publishing house) and " Chinese pharmacopoeia (version in 2005, Chemical Industry Press).
Chinese medicine composition of the present invention can also be routinely preparation process, for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record, make the acceptable any conventional dosage form of pharmaceutics, for example capsule, tablet, granule, powder, oral liquid or pill etc.
In the application of the present invention, described Chinese medicinal composition preparation dosage form is capsule, tablet, granule, powder, oral liquid or pill, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
The consumption of Chinese medicine composition of the present invention by active component crude drug gross weight, is 4-20 gram/day, but takes every day once, is preferably branch and takes for 2-4 time, also is preferably 6-12 gram/day, divides and takes for 2-4 time, more preferably 7.59 gram/days, divides and takes for 3 times.
For illustrating the activity that Chinese medicine composition of the present invention reduces malignant cytokine level, with having carried out following test by the prepared medicine of embodiment method (to call medicine of the present invention in the following text).
1, animal
Healthy Wistar rat, the cleaning level, male and female half and half, body weight 200～240g purchases in zoopery center, Hebei province, credit number: SCXK (Ji) 2003-1-003.Raising is in pharmacological room of Hebei Yiling Pharmaceutical Research Institute, illumination 12 hours/day, 20～23 ℃ of temperature, relative humidity 40～60%.Rat is raised in cages, 5/cage.Rat feed is a full-valence pellet feed, is provided by Hebei province's Experimental Animal Center.Adaptability was raised three days.
2, medicine
(lot number is provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd: 20060601), test is made into desired concn with distilled water to medicine of the present invention.
3, experimental technique
3.1 grouping and modeling
Rat is divided into 3 groups at random: sham operated rats, model group, medicine 4.8g crude drug of the present invention/kg dosage group.Every group 10.To desired concn, the administration volume is 10ml/kg to medicine with distilled water diluting, and route of administration is oral.
Adopt ventral aorta constriction legal system to make chronic heart failure (heart failure) rat model.Rat is used the pentobarbital sodium intraperitoneal injection of anesthesia, the xiphoid-process median incision of lower abdomen, divide the layer open abdominal cavity, at the free ventral aorta of the above passivity of renal artery branch, with No. 7 parallel the placing on the ventral aorta of syringe needle, with ventral aorta and together ligation of syringe, slowly syringe is withdrawn from then with 4 trumpeter's art silk threads, close abdomen, layering is sewed up.Making rat aorta diameter constriction is 0.7mm.Sham operated rats is opened the silk thread of will performing the operation behind the abdomen and is passed ventral aorta, and except that the constriction ventral aorta not, other operations are identical with model group.Postoperative 3 week beginning oral administration, once a day.4 weeks of successive administration.
3.2 observation index and method
Common carotid artery sacrificed by exsanguination rat, adopt radioimmunoassay method to measure Endothelin and tumor necrosis factor in the blood plasma: the operation by specification carries out.
3.3 statistical analysis
Experimental data adopts SPSS11.5 version software kit to carry out statistical procedures.Experimental data is represented with mean ± standard deviation.Use one factor analysis of variance, the P＜0.05 conduct inspection level that there was a significant difference.
4, result
Table 1 medicine of the present invention to the influence of rat plasma tumor necrosis factor and Endothelin (x ± S, n=10)
Compare with sham operated rats
*P＜0.05; Compare ##P＜0.01 with model group
As can be seen from Table 1, model group and sham operated rats relatively, TNF-α, ET level significantly raise (P＜0.01); Medicine group of the present invention and model group compare, and TNF-α, ET level be obviously decline (P＜0.01) all.
5, conclusion
Above experimentation shows that medicine of the present invention can obviously reduce heart failure rat ET level, reverses remodeling ventricle, improves cardiac function; Model group rat TNT-alpha levels obviously raises, and shows that TNF-α can increase the weight of cardiac function and hemodynamic deterioration, promotes the change of cardiac structure, and medicine of the present invention has the effect of this process of reverse.
In sum, medicine of the present invention can obviously reduce heart failure patient endothelin level (ET) and tumor necrosis factor (TNF-α) level.
The specific embodiment
Embodiment 1: the preparation of medicine capsule of the present invention
Prescription:
Radix Astragali 450g Radix Aconiti Lateralis Preparata 112.5g Radix Ginseng 225g Radix Salviae Miltiorrhizae 225g Semen Lepidii (Semen Descurainiae) 150g
Cortex Periplocae 180g Rhizoma Alismatis 225g Flos Carthami 90g Rhizoma Polygonati Odorati 75g Pericarpium Citri Reticulatae 75g Ramulus Cinnamomi 90g
Preparation method:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng, Cortex Periplocae are added 8 times of amount 70% alcohol reflux 2 times according to above-mentioned prescription, 3 hours for the first time, 2 hours for the second time, merge extractive liquid,, filter, decompression filtrate recycling ethanol is concentrated into relative density and is the clear paste of 1.25-1.30 (60 ℃ of heat are surveyed), and is standby;
(2) Ramulus Cinnamomi, Pericarpium Citri Reticulatae be according to the recipe quantity distillating extracting oil, and the aqueous solution of carrying behind the oil filters, and standby, residue adds 8 times of water gagings again and decocted 1 hour, filters, and merges decocting liquid, and is standby;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 9 times of amount decoctions of water 2 times, each 2 hours, merge extractive liquid,, filter, merge with Ramulus Cinnamomi, Pericarpium Citri Reticulatae decocting liquid in the step (2), being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, add ethanol in the stirring, left standstill below 70%, 4 ℃ 24 hours to determining alcohol, filter, decompression filtrate recycling ethanol, being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, mixes 65-70 ℃ of oven dry with the alcohol extraction clear paste of step (1);
(4) dried cream mixed powder is broken into 100 order powder, adds 70% ethanol and granulates in right amount, sprays into Ramulus Cinnamomi, Pericarpium Citri Reticulatae volatile oil, and mixing is encapsulated, makes 1000, promptly.
Embodiment 2: the preparation of medicinal tablet of the present invention
Prescription:
Radix Astragali 150g Radix Aconiti Lateralis Preparata 40g Radix Ginseng 225g Radix Salviae Miltiorrhizae 225g Semen Lepidii (Semen Descurainiae) 50g
Cortex Periplocae 180g Rhizoma Alismatis 75g Rhizoma Polygonati Odorati 75g Ramulus Cinnamomi 30g Flos Carthami 90g Pericarpium Citri Reticulatae 25g
Preparation method:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng, Cortex Periplocae are added 8 times of amount 70% alcohol reflux 2 times according to above-mentioned prescription, 3 hours for the first time, 2 hours for the second time, merge extractive liquid,, filter, decompression filtrate recycling ethanol is concentrated into relative density and is the clear paste of 1.25-1.30 (60 ℃ of heat are surveyed), and is standby;
(2) Ramulus Cinnamomi, Pericarpium Citri Reticulatae be according to the recipe quantity distillating extracting oil, and the aqueous solution of carrying behind the oil filters, and standby, residue adds 8 times of water gagings again and decocted 1 hour, filters, and merges decocting liquid, and is standby;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 9 times of amount decoctions of water 2 times, each 2 hours, merge extractive liquid,, filter, merge with Ramulus Cinnamomi, Pericarpium Citri Reticulatae decocting liquid in the step (2), being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, add ethanol in the stirring, left standstill below 70%, 4 ℃ 24 hours to determining alcohol, filter, decompression filtrate recycling ethanol, being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, mixes 65-70 ℃ of oven dry with the alcohol extraction clear paste of step (1);
(4) formulation method is made tablet routinely.
Embodiment 3: the preparation of medicine oral liquid of the present invention
Prescription:
Radix Astragali 250g Radix Aconiti Lateralis Preparata 112.5g Radix Codonopsis 200g Radix Salviae Miltiorrhizae 120g Semen Lepidii (Semen Descurainiae) 135g
CORTEX ACANTHOPANACIS 150g Rhizoma Alismatis 200g Rhizoma Polygonati Odorati 60g Ramulus Cinnamomi 75g Flos Carthami 75g Pericarpium Citri Reticulatae 60g
Preparation method: formulation method is made oral liquid routinely.
Claims (9)
1, a kind of Chinese medicine composition reduces application in the medicine of malignant cytokine level in preparation, it is characterized in that described Chinese medicine composition made by following bulk drugs:
Radix Astragali 150-450 part, Radix Aconiti Lateralis Preparata 40-120 part, Radix Ginseng or Radix Codonopsis 75-225 part, Radix Salviae Miltiorrhizae 75-225 part, Semen Lepidii (Semen Descurainiae) 50-150 part, Cortex Periplocae or CORTEX ACANTHOPANACIS 60-180 part, Rhizoma Alismatis 75-225 part, Rhizoma Polygonati Odorati 25-75 part, Ramulus Cinnamomi 30-90 part, Flos Carthami 30-90 part, Pericarpium Citri Reticulatae 25-75 part.
2, application as claimed in claim 1 is characterized in that described Chinese medicine composition made by following bulk drugs:
450 parts of the Radixs Astragali, 112.5 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 225 parts of Radix Codonopsis, 225 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 180 parts of CORTEX ACANTHOPANACIS, 225 parts of Rhizoma Alismatis, 75 parts of Rhizoma Polygonati Odorati, 90 parts of Ramulus Cinnamomi, 90 parts on Flos Carthami, 75 parts of Pericarpium Citri Reticulataes.
3, application as claimed in claim 1 is characterized in that described Chinese medicine composition made by following bulk drugs:
150 parts of the Radixs Astragali, 40 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 225 parts of Radix Codonopsis, 225 parts of Radix Salviae Miltiorrhizaes, 50 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 180 parts of CORTEX ACANTHOPANACIS, 75 parts of Rhizoma Alismatis, 75 parts of Rhizoma Polygonati Odorati, 30 parts of Ramulus Cinnamomi, 90 parts on Flos Carthami, 25 parts of Pericarpium Citri Reticulataes.
4, application as claimed in claim 1 is characterized in that described Chinese medicine composition made by following bulk drugs:
250 parts of the Radixs Astragali, 112.5 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 200 parts of Radix Codonopsis, 120 parts of Radix Salviae Miltiorrhizaes, 135 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 150 parts of CORTEX ACANTHOPANACIS, 200 parts of Rhizoma Alismatis, 60 parts of Rhizoma Polygonati Odorati, 75 parts of Ramulus Cinnamomi, 75 parts on Flos Carthami, 60 parts of Pericarpium Citri Reticulataes.
5, as each described application of claim 1-4, it is characterized in that the active component of described Chinese medicine composition is made by the following step:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng or Radix Codonopsis, Cortex Periplocae or CORTEX ACANTHOPANACIS are doubly measured 70% ethanol extraction with 7-9, filter, concentrated extracting solution to relative density when 60 ℃ of heat are surveyed is the clear paste of 1.25-1.30;
(2) volatile oil of extraction Ramulus Cinnamomi, Pericarpium Citri Reticulatae;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 6-10 times of water gaging decoction 2 times, and each 2 hours, merge extractive liquid, filtered; The aqueous solution that Ramulus Cinnamomi, Pericarpium Citri Reticulatae are carried behind the oil filters, and collects aqueous solution filtrate, adds 6-10 times of water gaging again and decocts residue 1 hour, filters, and merges aqueous solution; The various aqueous solutions of above-mentioned gained are merged, and being concentrated into relative density is the 1.25-1.30 clear paste, adds ethanol in the stirring, to determining alcohol 70%, leaves standstill, and filters, and filtrate is concentrated into that relative density is the clear paste of 1.25-1.30 when 60 ℃ of heat are surveyed.
As each described application among the claim 1-4, it is characterized in that 6, described Chinese medicine composition is capsule, tablet, granule, powder, oral liquid or pill as the pharmaceutical preparation of active component.
According to the preparation method of the described medicine capsule of claim 6, it is characterized in that 7, it is made up of following steps:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng or Radix Codonopsis, Cortex Periplocae or CORTEX ACANTHOPANACIS are proportionally measured take by weighing and added 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid,, filter, decompression filtrate recycling ethanol is concentrated into relative density and is the clear paste of 1.25-1.30 (60 ℃ of heat are surveyed), and is standby;
(2) Ramulus Cinnamomi, Pericarpium Citri Reticulatae distillating extracting oil proportionally, the aqueous solution of carrying behind the oil filters, and standby, residue adds 8 times of water gagings again and decocted 1 hour, filters, and merges decocting liquid, and is standby;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 9 times of amount decoctions of water 2 times, each 2 hours, merge extractive liquid,, filter, merge with Ramulus Cinnamomi, Pericarpium Citri Reticulatae decocting liquid in the step (2), being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, add ethanol in the stirring, left standstill below 70%, 4 ℃ 24 hours to determining alcohol, filter, decompression filtrate recycling ethanol, being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, mixes 65-70 ℃ of oven dry with the alcohol extraction clear paste of step (1);
(4) step (3) gained dried cream powder is broken into 100 order powder, adds 70% ethanol and granulate in right amount, spray into Ramulus Cinnamomi, Pericarpium Citri Reticulatae volatile oil, mixing, encapsulated, promptly.
8, as each described application among the claim 1-4, it is characterized in that the application of this Chinese medicine composition in preparation reduction plasma ET medicine.
9, as each described application among the claim 1-4, it is characterized in that the application of this Chinese medicine composition in the horizontal medicine of preparation reduction tumor necrosis factor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100551865A CN101590182A (en) | 2008-05-30 | 2008-05-30 | The application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100551865A CN101590182A (en) | 2008-05-30 | 2008-05-30 | The application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101590182A true CN101590182A (en) | 2009-12-02 |
Family
ID=41405182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100551865A Pending CN101590182A (en) | 2008-05-30 | 2008-05-30 | The application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101590182A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933339A (en) * | 2013-01-23 | 2014-07-23 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating depression |
| CN103933340A (en) * | 2013-01-23 | 2014-07-23 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating pneumoconiosis |
-
2008
- 2008-05-30 CN CNA2008100551865A patent/CN101590182A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933339A (en) * | 2013-01-23 | 2014-07-23 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating depression |
| CN103933340A (en) * | 2013-01-23 | 2014-07-23 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating pneumoconiosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101322801B (en) | Use of Chinese medicinal composition in preparing medicament for treating dilated cardiomyopathy | |
| CN104825791B (en) | A kind of traditional Chinese medicine health care product with anti-fatigue effect and preparation method thereof | |
| CN101632796B (en) | Application of Chinese medicinal composition in preparing medicament for treating acute heart failure | |
| CN103623341A (en) | Drug for treating hypertension and cardiovascular and cerebrovascular diseases caused by hypertension | |
| CN103520293A (en) | Oral traditional Chinese medicine for improving and treating constipation | |
| CN102579669A (en) | Chinese medicinal composition for nourishing qi and blood and conditioning menstruation and preparation method thereof | |
| CN101584807A (en) | Application of traditional Chinese medicine composition in preparing medicament of insulin sensitizer | |
| CN104000944B (en) | A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang | |
| CN101322792A (en) | Applications of Chinese medicinal composition in preparing medicament for improving function of vascular endothelium | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN102038864A (en) | Application of Chinese medicinal composition in preparation of medicament for treating diabetic cardiomyopathy | |
| CN102861230B (en) | Application of Chinese medicine composition in preparing medicines for treating organ fibrosis | |
| CN101590182A (en) | The application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level | |
| CN101099775B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN101590180A (en) | The application of a kind of Chinese medicine composition in preparation inhibition apoptosis of cardiac muscle medicine | |
| CN1730018B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and preparing process and application thereof | |
| CN101549070A (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN101683461B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for inhibiting oxidation damage | |
| CN101168018B (en) | Method for preparing 'rupikang' capsule | |
| CN102861231A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating ventricular remodeling after myocardial infarction | |
| CN108295131A (en) | A kind of composition of plant extracts, preparation method and application with antihypertensive effect | |
| CN105687208A (en) | Application of cycloastragenol in preparing medicine for treating cardiac failure | |
| CN103372138A (en) | Pharmaceutical composition containing effective components of Shengmai Yin and preparation method of pharmaceutical composition | |
| CN102416036B (en) | Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20091202 |